FDA WARNING_LETTER - Fair Price Labs, Inc. - July 21, 2020
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On July 24, 2020, the FDA issued a Warning Letter to FairPriceMD Inc. after reviewing their websites (www.fairpricelabs.com, www.fairpricemd.com) and social media pages on July 21, 2020. The letter addresses the sale of an at-home sample collection kit, referred to as the "covid-19 home test kit" or "DROPTM SARS-CoV-2 virus ELISA IgG and IgM Self-Collection Test Kit," intended for COVID-19 serology testing.
The FDA determined this product is a device under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the "Act"), 21 U.S.C. § 321(h), due to its intended use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. The product is deemed adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because FairPriceMD Inc. lacks an approved premarket approval (PMA) or investigational device exemption (IDE). It is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), as the firm failed
ID · 21637082-3622-4f0a-b826-61175e767c6d
Full citation text and observation details available on the Dashboard.